S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
This Tech Stock Could be the Next Amazon (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
This Tech Stock Could be the Next Amazon (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
This Tech Stock Could be the Next Amazon (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
This Tech Stock Could be the Next Amazon (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
This Tech Stock Could be the Next Amazon (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
This Tech Stock Could be the Next Amazon (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
This Tech Stock Could be the Next Amazon (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
This Tech Stock Could be the Next Amazon (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
This Tech Stock Could be the Next Amazon (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
This Tech Stock Could be the Next Amazon (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
This Tech Stock Could be the Next Amazon (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
This Tech Stock Could be the Next Amazon (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
NASDAQ:ANAB

AnaptysBio - ANAB Stock Forecast, Price & News

$21.76
+0.60 (+2.84%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$20.51
$22.08
50-Day Range
$21.16
$26.99
52-Week Range
$18.20
$32.44
Volume
244,594 shs
Average Volume
212,134 shs
Market Capitalization
$607.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.83

AnaptysBio MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
60.1% Upside
$34.83 Price Target
Short Interest
Bearish
18.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.49mentions of AnaptysBio in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.41) to ($4.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.31 out of 5 stars

Medical Sector

964th out of 1,004 stocks

Pharmaceutical Preparations Industry

468th out of 489 stocks


ANAB stock logo

About AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

ANAB Stock News Headlines

AnaptysBio: Upside Could Be Lying Ahead Very Nicely
AnaptysBio (NASDAQ:ANAB) Stock Price Down 3.3%
JP Morgan analyst: Oil to hit $380 per barrel
JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing. But there is one investment set to outperform all the rest.
AnaptysBio Announces Stock Repurchase Plan
JP Morgan analyst: Oil to hit $380 per barrel
JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing. But there is one investment set to outperform all the rest.
See More Headlines
Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

ANAB Company Calendar

Last Earnings
3/01/2023
Today
4/01/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANAB
Fax
N/A
Employees
102
Year Founded
2005

Price Target and Rating

Average Stock Price Forecast
$34.83
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+60.1%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-128,720,000.00
Net Margins
-1,251.33%
Pretax Margin
-1,251.09%

Debt

Sales & Book Value

Annual Sales
$10.29 million
Book Value
$9.22 per share

Miscellaneous

Free Float
18,462,000
Market Cap
$607.76 million
Optionable
Optionable
Beta
-0.11

Social Links


Key Executives

  • Daniel R. Faga
    President, Chief Executive Officer & Director
  • Eric J. LoumeauEric J. Loumeau
    Chief Operating Officer & General Counsel
  • Dennis M. Mulroy
    Chief Financial Officer
  • Paul F. Lizzul
    Chief Medical Officer
  • David McKeon
    Vice President & Controller













ANAB Stock - Frequently Asked Questions

Should I buy or sell AnaptysBio stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ANAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View ANAB analyst ratings
or view top-rated stocks.

What is AnaptysBio's stock price forecast for 2023?

5 Wall Street analysts have issued 1 year price targets for AnaptysBio's shares. Their ANAB share price forecasts range from $28.00 to $44.00. On average, they anticipate the company's stock price to reach $34.83 in the next year. This suggests a possible upside of 60.1% from the stock's current price.
View analysts price targets for ANAB
or view top-rated stocks among Wall Street analysts.

How have ANAB shares performed in 2023?

AnaptysBio's stock was trading at $30.99 at the beginning of the year. Since then, ANAB shares have decreased by 29.8% and is now trading at $21.76.
View the best growth stocks for 2023 here
.

Are investors shorting AnaptysBio?

AnaptysBio saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 4,590,000 shares, an increase of 7.2% from the February 28th total of 4,280,000 shares. Based on an average trading volume of 304,200 shares, the days-to-cover ratio is presently 15.1 days. Currently, 18.1% of the company's shares are sold short.
View AnaptysBio's Short Interest
.

When is AnaptysBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our ANAB earnings forecast
.

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings data on Wednesday, March, 1st. The biotechnology company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by $0.01. The biotechnology company earned $6.81 million during the quarter, compared to the consensus estimate of $8.20 million. AnaptysBio had a negative trailing twelve-month return on equity of 43.83% and a negative net margin of 1,251.33%.

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

When did AnaptysBio IPO?

(ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

How do I buy shares of AnaptysBio?

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $21.76.

How much money does AnaptysBio make?

AnaptysBio (NASDAQ:ANAB) has a market capitalization of $607.76 million and generates $10.29 million in revenue each year. The biotechnology company earns $-128,720,000.00 in net income (profit) each year or ($4.57) on an earnings per share basis.

How many employees does AnaptysBio have?

The company employs 102 workers across the globe.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.anaptysbio.com. The biotechnology company can be reached via phone at (858) 362-6295 or via email at investors@anaptysbio.com.

This page (NASDAQ:ANAB) was last updated on 4/1/2023 by MarketBeat.com Staff